| Similar Articles |
|---|
 |
The Motley Fool
May 7, 2008
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's at it this week?   |
The Motley Fool
July 24, 2008
Tim Beyers |
Who's Buying Now? Insider purchases: Flagstar Bancorp... Marriott International... U.S. Bancorp... ValueClick... Wachovia... |
The Motley Fool
June 12, 2008
Tim Beyers |
Who's Buying Now? Insider trades: China Security & Surveillance... Jarden.. Masco... MVC Capital... Wells Fargo... |
The Motley Fool
June 6, 2007
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Brookdale Senior Living... Genomic Health... Green Plains Renewable Energy... Sunesis Pharmaceuticals... etc. |
The Motley Fool
September 19, 2007
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Caribou Coffee... Citizen's Communications... L-1 Identity Solutions... MVC Capital... ZymoGenetics... |
The Motley Fool
April 11, 2007
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Hawaiian Holdings... IndyMac Bancorp... Martek Bioscience... etc. |
The Motley Fool
January 21, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week? Take a look at insider buying at these companies: A. Schulman... Greenbrier Companies... Oracle... Stericycle... Worthington Industries... |
The Motley Fool
December 26, 2007
Tim Beyers |
Who's Buying Now? Insider purchases: General Growth Properties...Isle of Capri Casinos... NCI Building Systems... Resources Connection... Universal Forest Products... |
The Motley Fool
June 4, 2008
Tim Beyers |
Who's Buying Now? Insider buying: Checkpoint Systems... Chesapeake Energy... General Electric... Valeant Pharmaceuticals... Virtual Radiologic... |
The Motley Fool
April 30, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week? |
The Motley Fool
January 28, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week? |
The Motley Fool
July 30, 2008
Tim Beyers |
Who's Buying Now? Insider buying: Albermarle... Allegheny Technologies... eBay... Flagstar Bancorp... Regions Financial... |
The Motley Fool
October 27, 2010
Tim Beyers |
Pretty Up Your Portfolio With This Beauty of a Stock Ulta Salon shows all the signs of sustainable growth. |
The Motley Fool
October 12, 2006
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? ConAgra Foods... Goodrich Petroleum... Hallmark Financial Services... NeoPharm... Prospect Energy... |
The Motley Fool
December 16, 2008
Tim Beyers |
Sell Oracle? Bah! Humbug! Oracle reports earnings this Thursday, and Wall Street isn't expecting good news. But there's still much to like about this company. |
The Motley Fool
April 24, 2008
Brian Orelli |
Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs. |
BusinessWeek
May 14, 2007
Arlene Weintraub |
Schering-Plough Climbs Out Of Its Sickbed Fred Hassan said getting drugmaker Schering-Plough on its feet might take years. Investors are beginning to see the virtues of patience |
The Motley Fool
April 4, 2008
Brian Orelli |
Why Is Schering Cutting Now? The latest pharmaceutical company to jump on the cost-cutting bandwagon is Schering-Plough. |
The Motley Fool
April 4, 2008
Toby Shute |
Top Secret Energy Plays These two relatively unheard of companies tap two of the hottest investment themes out there: offshore drilling and alternative energy. Read on for more. |
The Motley Fool
April 21, 2005
Stephen D. Simpson |
Schering-Plough Back in Black The turnaround seems to be working, as the company puts together consecutive quarters of good growth. But investors must realize that the company has a rather sparse late-stage pipeline relative to other large pharmaceutical peers. |
The Motley Fool
January 25, 2005
Stephen D. Simpson |
Schering-Plough Turning a Corner The troubled pharmaceutical company begins to show signs of life. Investors looking for a more stable play would do well to look at other shares instead. |
The Motley Fool
July 24, 2006
Stephen D. Simpson |
Can Schering-Plough Continue to Shine? Cost-cutting and cholesterol drug sales continue apace, but is the company vulnerable? Investors, take note. |
The Motley Fool
October 21, 2008
Brian Orelli |
Schering Buys Great Growth Acquiring Organon Biosciences saves the company from a rough quarter. |
The Motley Fool
March 13, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend by hitting new highs. Take a look at: Schering-Plough... AutoZone... |
The Motley Fool
September 22, 2008
Brian Orelli |
Let's Bail Out Pharma Next Schering-Plough is cutting jobs. Maybe the government should help out? |
The Motley Fool
March 31, 2008
Brian Orelli |
No Blood-Pumping Love for Merck and Schering From the reports coming out of the American College of Cardiology meeting, it looks like the drugmakers Merck and Schering-Plough took a beating. |
The Motley Fool
August 7, 2007
Brian Orelli |
Financing Your Acquisition Schering-Plough is one step closer to financing its $14 billion acquisition of the Organon BioSciences unit of Akzo Nobel, by making an official stock offering. |
BusinessWeek
October 2, 2006
Gene G. Marcial |
Shopping For Schering? The buzz about Schering-Plough on Wall Street is that the company is in play. |
The Motley Fool
August 16, 2011
Cindy Johnson |
5 Energy Equipment and Services Stocks the Insiders Are Buying Folks in the know think these energy stocks will rise: Exterran Holdings... Hercules Offshore... ION Geophysical... Gulf Island Fabrication... Vantage Drilling... |
The Motley Fool
February 4, 2009
Brian Orelli |
The Tale of 2 Drugmakers Merck and Schering-Plough typically release earnings on the same day because they share sales of cholesterol drugs Vytorin and Zetia, but the drugmakers are far from the same. |
The Motley Fool
May 21, 2009
Brian Orelli |
Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose. |
The Motley Fool
May 1, 2009
Brian Orelli |
Catch the Perps Already Biotech may be the sector most susceptible to insider trading because there are so many binary events that can drastically change the stock price of a company in a very short time frame. |
The Motley Fool
October 24, 2005
Stephen D. Simpson |
Vytorin Lifts Schering-Plough While the pharma is now officially in a turnaround phase, the news may already be baked into the stock. |
The Motley Fool
July 21, 2005
Stephen D. Simpson |
Schering Plows Ahead Strong sales are driving this turnaround. As long as the pharma continues to make progress with its legal and regulatory issues and simultaneously continue to deliver solid financial results, the valuation and stock price will likely work themselves out favorably over time. |
The Motley Fool
March 10, 2011
Esterhuizen & Sellitti |
Bearish Options vs. Bullish Insiders: Whose Side Are You On? We put together a list of stocks that have seen significant increases in their put/call ratios, but continue to see insider buying. |
The Motley Fool
March 2, 2010
Brian Orelli |
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
Speed the Plough Schering-Plough is still in a precarious position, but it's likely to have above-average growth. It is also one of the few pharmaceuticals whose risk level is actually decreasing. This could be a stock worth owning for some time. |
The Motley Fool
April 20, 2006
Stephen D. Simpson |
Could Schering-Plough Do More With More? An acquisition or two might make better use of the company's overhead. There could be some upside here for investors as the recovery story continues to play out. |
The Motley Fool
January 26, 2004
Jeff Hwang |
On Schwab's Insider Sales After closer inspection, Schwab CEO's plan to sell is no big deal. |
The Motley Fool
October 21, 2011
Alexander Crawford |
9 Energy Stocks Being Bought Up by Company Insiders Do you agree with these insiders on their bullish company outlooks?: Vantage Drilling... Star Gas Partners... PHI... Energy Partners... Global Partners... SandRidge Energy... QR Energy... Rex Energy... NuStar GP Holdings... |
The Motley Fool
September 2, 2008
Brian Orelli |
Cardiologists Hate Vytorin Cardiologists seem cynical about the full presentation of Merck's and Schering-Plough's SEAS data at the European Society of Cardiology. |
The Motley Fool
February 14, 2008
Brian Orelli |
A Lovey-Dovey Duo Drug companies Schering-Plough and Merck hook up to market a 'hot, hot, hot!' product. |
The Motley Fool
March 9, 2011
Esterhuizen & Sellitti |
Beaten Up Stocks Being Snapped Up by Insiders: Should You Go Bargain Hunting? If you want to find the diamonds in the rough, you'll have to do more than guesswork. Do you agree with these insiders buying these downtrodden stocks? |
The Motley Fool
July 8, 2010
Brian Orelli |
Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy. |
The Motley Fool
February 16, 2010
Brian Orelli |
Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped. |
The Motley Fool
November 9, 2011
Sean Williams |
Should You Buy What Insiders Are Selling? Insider selling dramatically picks up in the month of October. |
The Motley Fool
October 23, 2007
Brian Orelli |
Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth. |
The Motley Fool
November 25, 2009
Brian Orelli |
A Schizophrenic Move by Merck? Issue $29 billion in shares, buy back $3 billion. Say what? Merck increased its share count by almost 45% to pay for the acquisition of Schering-Plough. Now it's planning to buy some of that stock back. |
The Motley Fool
April 21, 2009
Brian Orelli |
Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%. |
The Motley Fool
April 22, 2008
Brian Orelli |
Will Merck Make It? Merck releases first-quarter results and says it can meet its previous guidance. |
